Ameet Sarpatwari

Ameet Sarpatwari, PhD, JD

Faculty Member of the Center
Member, HMS Center for Bioethics

Ameet Sarpatwari is an Assistant Professor of Population Medicine at the Harvard Pilgrim Health Care Institute and Harvard Medical School. His research draws upon his interdisciplinary training as an epidemiologist and lawyer and focuses on the effects of laws and regulations on therapeutic development, approval, use, and related public health outcomes.

Dr. Sarpatwari's work has been highly influential. His writing and resulted in multiple invitations to testify before Congress and state legislatures, to discuss proposed legislation with Hill staffers, and to be approached routinely for insight on pharmaceutical policy by reporters from such prominent news sources as the New York Times, Washington Post, and NPR.

In addition to his primary position within the Institute's division of Health Policy and Insurance Research, Dr. Sarpatwari is also a faculty member in the Center for Bioethics at Harvard Medical School, the Department of Health Policy and Management at the Harvard T.H. Chan School of Public Health ("Harvard Chan School"), and the Harvard-MIT Center for Regulatory Science. At the Harvard Chan School, he serves as the Faculty Director of the JD/MPH program and teaches a highly acclaimed class on public health law.

Dr. Sarpatwari completed his undergraduate studies at the University of Virginia, where he was a Jefferson Scholar. He studied epidemiology at the University of Cambridge, where he received a Ph.D. He subsequently studied law at the University of Maryland as a John L. Thomas Leadership Scholar. Following his legal studies, he joined the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital and Harvard Medical School as a post-doctoral fellow. He remained with PORTAL, serving as its Assistant Director for several years.

Publications View
Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims.
Authors: Authors: Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA, Kesselheim AS, Gagne JJ.
PLoS Med
View full abstract on Pubmed
Tepid Steps on Drug Pricing.
Authors: Authors: Sarpatwari A, Kesselheim AS.
JAMA Intern Med
View full abstract on Pubmed
Mitigating Health Risks of Prescription Drugs: Lessons From FDA Oversight of Opioid Products.
Authors: Authors: Sarpatwari A, Curfman G.
JAMA
View full abstract on Pubmed
Role of Authorized Generics in Postapproval Surveillance of Generic Drug Products.
Authors: Authors: Gagne JJ, Sarpatwari A, Desai RJ.
Clin Pharmacol Ther
View full abstract on Pubmed
New Drug Formulations and Their Respective Generic Entry Dates.
Authors: Authors: Beall RF, Kesselheim AS, Sarpatwari A.
J Manag Care Spec Pharm
View full abstract on Pubmed
Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.
Authors: Authors: Rogers JR, Sarpatwari A, Desai RJ, Bohn JM, Khan NF, Kesselheim AS, Fischer MA, Gagne JJ, Connolly JG.
Drug Saf
View full abstract on Pubmed
The US Biosimilar Market: Stunted Growth and Possible Reforms.
Authors: Authors: Sarpatwari A, Barenie R, Curfman G, Darrow JJ, Kesselheim AS.
Clin Pharmacol Ther
View full abstract on Pubmed
The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later.
Authors: Authors: Avorn J, Kesselheim A, Sarpatwari A.
N Engl J Med
View full abstract on Pubmed
Promoting Patient Interests in Implementing the Federal Right to Try Act.
Authors: Authors: Lynch HF, Zettler PJ, Sarpatwari A.
JAMA
View full abstract on Pubmed
An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
Authors: Authors: Sarpatwari A, Avorn J, Kesselheim AS.
JAMA
View full abstract on Pubmed

Address: 
Brigham and Women's Hospital
General Medicine-OBC-3030, N2
1620 Tremont St
Boston, MA 02120